Drug Trial Radar · NCT01879722
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Jun 2013
Primary completion
Jun 2014
Study completion Jun 2014
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 18, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.
Conditions
- Schizophrenia
Interventions
TAK-063Drug
TAK-063 tablets
TAK-063 PlaceboDrug
TAK-063 placebo-matching tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) After 7 Days of DosingTime frame: Day 1 to Day 14
- Percentage of Participants With Markedly Abnormal Safety Laboratory TestsTime frame: Day 1 to Day 8
- Percentage of Participants With Markedly Abnormal Vital Sign MeasurementsTime frame: Day 1 to Day 8
- Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) ParametersTime frame: Day 1 to Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.